Rheumatology Book

http://www.fpnotebook.com/

Teriparatide

Aka: Teriparatide, Forteo
  1. Mechanism
    1. Recombinant Parathyroid Hormone
    2. Significant bone anabolic activity
  2. Indications: Severe Osteoporosis
    1. Women, postmenopausal, with severe bone loss
    2. Men with Osteoporosis and high risk of Fracture
    3. Osteoporosis refractory to Bisphosphonates
  3. Dose
    1. Teriparatide 20 mcg SQ daily for up to 2 years
    2. Consider restarting bisphosphonate after Teriparatide course is completed
      1. Black (2005) N Engl J Med 353(6):555-65
  4. Efficacy
    1. BMD increases 5.9% at spine and 1.5% at femoral neck
    2. Reduced risk for osteoporotic Fractures
      1. Neer (2001) N Engl J Med 344:1434-41
  5. Contraindications
    1. Hyperparathyroidism
    2. Osteomalacia
    3. End Stage Renal Disease
    4. Bone cancer
    5. Active Nephrolithiasis
    6. Hypercalcemia
    7. Osteosarcoma risk
      1. Paget's Disease
      2. Prior skeletal radiation
      3. Elevated Alkaline Phosphatase level
  6. Adverse Effects
    1. Common
      1. Orthostatic Hypotension
      2. Transient Hypercalcemia
      3. Nausea
      4. Arthralgia
      5. Leg cramps
    2. Uncommon (identified in rat studies)
      1. Osteosarcoma
  7. Precautions
    1. Do not use with bisphosphonate
    2. Use limited to 2 year maximum
  8. Resources
    1. National Osteoporosis Foundation Clinicians Guide To Osteoporosis
      1. http://www.nof.org/professionals/Clinicians_Guide.htm
  9. References
    1. Campion (2003) Am Fam Physician 67(7):1521-6
    2. Orwoll (2003) J Bone Miner Res 18:9-17

Forteo (C1170286)

Concepts Amino Acid, Peptide, or Protein (T116) , Pharmacologic Substance (T121)
MSH D019379
English Lilly Brand of Teriparatide, Teriparatide Lilly Brand, forteo, Forteo
French Forteo
German Forteo
Sources
Derived from the NIH UMLS (Unified Medical Language System)


Teriparatide (C0070093)

Definition (MSH) A polypeptide that consists of the 1-34 amino-acid fragment of human PARATHYROID HORMONE, the biologically active N-terminal region. The acetate form is given by intravenous infusion in the differential diagnosis of HYPOPARATHYROIDISM and PSEUDOHYPOPARATHYROIDISM. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)
Concepts Amino Acid, Peptide, or Protein (T116) , Pharmacologic Substance (T121) , Hormone (T125)
MSH D019379
SnomedCT 425438001, 398823001
English hPTH (1-34), Human Parathyroid Hormone (1-34), TERIPARATIDE @ @ UNIDENTIFIED, TERIPARATIDE UNIDENTIFIED, HPTH 001 034, Teriparatide (substance), Teriparatide, Human PTH (1-34), (1-34)-Human Parathyroid Hormone, Teriparatide [Chemical/Ingredient], parathyroid teriparatide, teriparatide (medication), teriparatide, Teriparatide (product), TERIPARATIDE
Swedish Teriparatid
Czech teriparatid
Spanish teriparatida (sustancia), teriparatida (producto), teriparatida, teriparatide, Hormona Paratiroidea Humana (1-34), hPTH (1-34), Teriparatido
Finnish Teriparatidi
French hPTH (1-34), Hormone parathyroïdienne humaine (1-34), Tériparatide
Russian TERIPARATID, PARATIREOIDNYI GORMON (1-34) CHELOVEKA, ПАРАТИРЕОИДНЫЙ ГОРМОН (1-34) ЧЕЛОВЕКА, ТЕРИПАРАТИД
Japanese ヒト副甲状腺ホルモン(1-34), テリパラチド, 酢酸テリパラチド, フォルテオ, テリパラチド酢酸塩
Italian Ormone paratiroideo umano (1-34), hPTH (1-34), Teriparatide
German HPTH 001 034, Humanes Parathormon (1-34), Teriparatid, hPTH (1-34)
Polish Teryparatyd, hPTH 1-34, Hormon przytarczyc ludzki 1-34
Portuguese Hormônio (1-34) da Paratireóide Humana, Hormônio (1-34) Paratireóideo Humano, Hormônio Paratireóideo Humano (1-34), hPTH (1-34), Teriparatida
Sources
Derived from the NIH UMLS (Unified Medical Language System)


Navigation Tree